LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Financials Overview

Financials in millions CAD. Fiscal year is May - April.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
Operating Income Operating Income Growth	-2.33	-0.32	-0.08
Net Income Net Income Growth	-2.61	-0.32	-0.08
Earnings Per Share EPS Growth	-0.12	-0.06	-6.33
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
Cash & Investments Cash & Investments Growth	0.92	0.12	0.2
Total Debt Total Debt Growth	-	-	0.19
Net Cash (Debt) Net Cash Growth	0.92	0.12	0
Net Cash Growth	1122779.27%	147336.58%	-
Net Cash Per Share Net Cash Per Share Growth	0.04	0.02	0.01

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
Operating Cash Flow Operating Cash Flow Growth	-1.64	-0.19	0
Free Cash Flow Free Cash Flow Growth	-1.64	-0.19	0
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jan 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 8, 2026

Data Sources Report a data error